This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Change history
28 October 2022
The name of Ana Jimenez Ubieto was given incorrect in HTML version of the article. Correct is: Given name: Ana Family name: Jimenez Ubieto.
References
Klyuchnikov E, von Pein UM, Ayuk FA, Christopeit M, Adjalle R, van Randenborgh A, et al. Daratumumab is an effective and safe salvage therapy in relapsed/refractory patients with multiple myeloma after allogeneic stem cell transplantation. Blood. 2016;128:3437.
Krishnan A, Parameswaran H, Chhabra S, Biran N, Stiller T, Htut M, et al. Incidence and timing of graft versus host disease (GVHD) after daratumumab (Dara) anti CD38 therapy post allogeneic transplant (alloHCT) for myeloma. Clin Lymphoma Myeloma Leuk. 2017;17:e71.
Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551–60. https://doi.org/10.1016/S0140-6736(15)01120-4.
Lavi N, Okasha D, Sabo E, Oren I, Benyamini N, Bar-Yoseph H. Severe cytomegalovirus enterocolitis developing following daratumumab exposure in three patients with multiple myeloma. Eur J Haematol. 2018;101:699–702. https://doi.org/10.1111/ejh.13164.
Frerichs KA, Bosman PWC, Nijhof IS, Zweegman S, van de Donk N. Cytomegalovirus reactivation in a patient with extensively pretreated multiple myeloma during daratumumab treatment. Clin Lymphoma Myeloma Leuk. 2019;19:e9–e11. https://doi.org/10.1016/j.clml.2018.10.002.
Acknowledgments
This study was supported in part by the Spanish grant of Instituto de Salud Carlos III (PI16/01485) and FEDER European Union.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
APG-R has served as speaker and member of advisory boards from Janssen and Celgene and Takeda. MVM has served as speaker and member of advisory boards from Janssen, Amgen, Celgene, Takeda, GSK, Abbvie, EDO, and Pharmamar. LR has served as speaker and member of advisory boards from Janssen, Amgen, Celgene, and Takeda. MAH has served as speaker and member of advisory boards from Janssen, Amgen, Celgene, and Takeda. LLC, DFM, AJG-H, PP, AB, TZR, PSD, SG-M, JZ, AJU, FdeA, CS-B, AL-S, and SG declare that they have no conflict of interest.
Additional information
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gonzalez-Rodriguez, A.P., Lopez-Corral, L., Fajardo, D.F.M. et al. Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT. Bone Marrow Transplant 55, 461–463 (2020). https://doi.org/10.1038/s41409-019-0525-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-019-0525-1
This article is cited by
-
Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT
Bone Marrow Transplantation (2022)
-
Daratumumab
Reactions Weekly (2020)